NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the fourth quarter and full-year 2016 and provided detailed financial guidance for the full-year 2017.
"The fourth quarter was the strongest in our history, capping a year of great execution and giving us great momentum as we enter 2017," said Tarek Sherif, Medidata's chairman and chief executive officer. "Our results show that our relentless commitment to innovation and our flawless execution are driving the commercial success of our platform. Our dedication to helping transform how healthcare solutions are developed and delivered is embedded in Medidata’s DNA, and is rapidly being embraced by the world’s leading life sciences companies—driving better research, more personalized medicines and ultimately improved patient outcomes."
Fourth Quarter 2016 Results
- Total revenue for the fourth quarter of 2016 was $124.5 million, an increase of $25.6 million, or 26%, compared with $98.9 million in the fourth quarter of 2015. Subscription revenue was $106.0 million, an increase of $21.3 million, or 25%, compared with the same period last year.
- Professional services revenue for the fourth quarter of 2016 was $18.5 million, an increase of $4.3 million, or 30%, compared with $14.2 million in the fourth quarter of 2015.
- GAAP operating income for the quarter was $17.5 million, up 81%, compared with $9.7 million in the fourth quarter of 2015. Non-GAAP operating income2 for the fourth quarter of 2016 increased to $31.9 million, up 35%, compared with $23.6 million a year ago.
- GAAP net income for the fourth quarter of 2016 was $10.8 million, or $0.19 per diluted share, up 59%, compared with $6.8 million, or $0.12 per diluted share, in the fourth quarter of 2015. Adjusted non-GAAP net income2 for the fourth quarter of 2016 was $19.2 million, or $0.33 per diluted share, up 24%, compared with $15.5 million, or $0.27 per diluted share, in the fourth quarter of 2015. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments.
- Cash flow from operations was $40.4 million in the fourth quarter of 2016, an increase of $10.0 million, or 33%, compared with $30.4 million a year ago.
Full-Year 2016 Results
- Total revenue for the full-year 2016 was $463.4 million, an increase of $70.9 million, or 18%, compared with $392.5 million in 2015. Subscription revenue was $394.3 million, an increase of $58.1 million, or 17%, over 2015.
- Professional services revenue for the full-year 2016 was $69.1 million, an increase of $12.8 million, or 23%, compared with $56.3 million in 2015.
- GAAP operating income for the full-year 2016 was $50.2 million, up 72%, compared with $29.2 million in 2015. Non-GAAP operating income2 for the full year increased to $106.7 million, up 20%, compared with $89.0 million in 2015.
- GAAP net income for the full-year 2016 was $29.0 million, or $0.51 per diluted share, up 120%, compared with $13.2 million, or $0.23 per diluted share, in 2015. Adjusted non-GAAP net income2 for the full year was $62.8 million, or $1.10 per diluted share, up 24%, compared with $50.8 million, or $0.90 per diluted share, in 2015. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments.
- Cash flow from operations was $88.8 million for the full-year 2016 compared with $88.6 million in 2015.
- Total cash, cash equivalents and marketable securities were $515.2 million at the end of 2016, an increase of $36.5 million, or 8%, compared with $478.7 million on December 31, 2015.
- Adjusted subscription backlog1 as of December 31, 2016 was $404 million, an increase of $70 million, or 21%, compared with $334 million a year ago. Adjusted subscription backlog, together with professional services revenue guidance, provides 87% coverage of total revenue based on the midpoint of our full-year 2017 total revenue guidance range.
- In 2016, Medidata closed enterprise platform deals with multiple top-25 pharmaceutical companies, including Bristol-Myers Squibb and Celgene. This continued adoption of the Medidata Clinical Cloud® further reinforces that it is the technology platform of choice for top life sciences companies looking to transform their drug development programs, and positions Medidata for long-term future growth.
- In February 2017, Medidata announced that it is adding regulated document and content management capabilities to the Medidata Clinical Cloud. Medidata is acquiring CHITA and partnering with Box to create the industry’s first integrated, end-to-end platform for all R&D content and data management.
- Medidata saw significant acceleration in its data analytics business with 16 deals signed in 2016, showing particular strength in Centralized Statistical Analytics (CSA), which was adopted by Bristol-Myers Squibb and Celgene.
- Medidata Payments®—the market’s only end-to-end, global payment solution to trigger, calculate and disburse payments around the globe—was recognized as the “Best Technological Development in Clinical Trials” at the 2016 Scrip Awards.
- Medidata added a record 288 new clients in 2016, an increase of 43% over 2015, including 66 new clients in the fourth quarter. Medidata's client base grew to 849 by the end of the year, up 39% from the end of 2015.
- 79% of clients3 had committed to multiple products at the end of 2016, up from 67% at the end of 2015.
“Medidata is consistently delivering on its promise and outperformed its guidance for the full-year 2016,” said Rouven Bergmann, Medidata’s chief financial officer. “We enter 2017 with excellent momentum. Our subscription backlog provides strong visibility, giving us the confidence to target accelerated subscription revenue growth and significant profit expansion in our 2017 outlook."
For the full-year 2017, the Company now expects:
- Total revenue between $538 and $562 million, representing up to 21% year-over-year growth at constant currency.
- Professional services revenues of approximately $75 million.
- GAAP operating income between $61 and $69 million. Non-GAAP operating income, which excludes the impact of depreciation, amortization of intangible assets, and stock-based compensation expense, between $131 and $139 million.
- GAAP net income between $31 and $36 million. Adjusted non-GAAP net income, which excludes the impact of stock-based compensation, non-cash interest expense associated with convertible senior notes, and amortization, tax-affected at a 40% rate, between $69 and $74 million.
- While changes in the stock price could change the fully diluted share count, the Company is now assuming 58.2 million fully diluted shares.
The operating and net income measures above reflect the Company’s non-GAAP financial guidance and the corresponding GAAP equivalents to its guidance.
The Company plans to host its investor conference call today at 8:00 a.m. Eastern time. The investor conference call will be available via live webcast on the “Investor” section of Medidata’s website at http://investor.mdsol.com. To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the “Investor” section of Medidata’s website at http://investor.mdsol.com. A replay of the conference call can be accessed until Thursday, February 23, 2017 by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 52493043. An archive of the call will also be hosted on the “Investor” section of Medidata’s website, http://investor.mdsol.com, for a limited period of time.
Medidata is reinventing global drug development by creating the industry's leading cloud-based solutions for clinical research. Through our advanced applications and intelligent data analytics, Medidata helps advance the scientific goals of life sciences customers worldwide, including over 800 global pharmaceutical companies, innovative biotech, diagnostic and device firms, leading academic medical centers, and contract research organizations.
The Medidata Clinical Cloud® brings a new level of quality and efficiency to clinical trials that empower our customers to make more informed decisions earlier and faster. Our unparalleled clinical trial data assets provide deep insights that pave the way for future growth. The Medidata Clinical Cloud is the primary technology solution powering clinical trials for 17 of the world's top 25 global pharmaceutical companies, from study design and planning through execution, management and reporting.
Certain statements made in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. (“Medidata”), including but not limited to statements about Medidata’s forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the Company, see disclosures contained in Medidata’s public filings with the Securities and Exchange Commission, including the “Risk Factors” section of Medidata’s Annual Report on Form 10-K for the year ended December 31, 2015. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information.
(1) Adjusted subscription backlog equals subscription backlog plus outstanding intra-year renewals valued at an amount equal to the contracts to be renewed.
(2) Non-GAAP Financial Information
Medidata provides non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, and stock-based compensation expense. Adjusted non-GAAP net income excludes the tax-affected impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, and non-cash interest expense on convertible senior notes. Management uses these non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation, amortization and other non-cash charges, such as share-based compensation, and management believes, based on discussions with investors, that these non-GAAP measures enhance investors’ ability to assess Medidata’s historical and projected future financial performance. While management believes these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of non-GAAP financial measures. One limitation of non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are attached to this press release.
(3) Excludes medical imaging-only customers.
|MEDIDATA SOLUTIONS, INC.|
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|(Amounts in thousands, except per share data)|
Three Months Ended
Twelve Months Ended
|Cost of revenues (1)(2)|
|Total cost of revenues||29,656||21,908||112,609||89,788|
|Operating costs and expenses:|
|Research and development (1)||28,072||23,697||112,595||92,319|
|Sales and marketing (1)(2)||28,434||27,230||109,290||103,153|
|General and administrative (1)||20,812||16,359||78,678||78,014|
|Total operating costs and expenses||77,318||67,286||300,563||273,486|
|Interest and other income (expense):|
|Other income (expense), net||19||1||11||(64||)|
|Total interest and other expense, net||(3,166||)||(3,284||)||(12,895||)||(13,457||)|
|Income before income taxes||14,332||6,391||37,314||15,775|
|Provision for income taxes||3,492||(425||)||8,331||2,608|
|Earnings per share:|
|Weighted average common shares outstanding:|
|(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses is as follows:|
|Cost of revenues||$||822||$||1,235||$||4,425||$||5,040|
|Research and development||2,414||2,003||9,223||7,907|
|Sales and marketing||1,725||2,001||7,074||9,171|
|General and administrative||5,042||5,840||20,436||26,869|
|Total stock-based compensation||$||10,003||$||11,079||$||41,158||$||48,987|
|(2) Amortization of intangible assets included in costs of revenues and operating costs and expenses is as follows:|
|Cost of revenues||$||314||$||79||$||1,021||$||517|
|Sales and marketing||83||30||276||119|
|Total amortization of intangible assets||$||397||$||109||$||1,297||$||636|
|MEDIDATA SOLUTIONS, INC.|
Reconciliation of GAAP Operating Income and GAAP Net Income to
Non-GAAP Operating Income and Adjusted Non-GAAP Net Income (Unaudited)
|(Amounts in thousands, except per share data)|
Three Months Ended
Twelve Months Ended
|GAAP operating income||$||17,498||$||9,675||$||50,209||$||29,232|
|GAAP operating margins||14.1||%||9.8||%||10.8||%||7.4||%|
|Depreciation and amortization||4,448||2,881||15,349||10,822|
|Non-GAAP operating income||$||31,949||$||23,635||$||106,716||$||89,041|
|Non-GAAP operating margins||25.7||%||23.9||%||23.0||%||22.7||%|
|GAAP net income||$||10,840||$||6,816||$||28,983||$||13,167|
|Non-cash interest expense on convertible senior notes (1)||3,550||3,363||13,914||13,180|
|Tax impact on add-back items (2)||(5,580||)||(5,820||)||(22,548||)||(25,121||)|
|Adjusted non-GAAP net income||$||19,210||$||15,547||$||62,804||$||50,849|
|GAAP basic earnings per share||$||0.19||$||0.13||$||0.52||$||0.25|
|GAAP diluted earnings per share||$||0.19||$||0.12||$||0.51||$||0.23|
|Adjusted non-GAAP basic earnings per share||$||0.34||$||0.29||$||1.13||$||0.95|
|Adjusted non-GAAP diluted earnings per share||$||0.33||$||0.27||$||1.10||$||0.90|
(1) Amount represents non-cash interest expense, including amortization of debt discount and issuance costs, on our 1.00% convertible senior notes. We exclude this incremental non-cash interest expense for purposes of calculating adjusted non-GAAP net income. We believe that excluding these expenses from our non-GAAP measures is useful to investors because such incremental non-cash interest expense does not generate a cash outflow for the Company and the debt issuance costs do not represent a cash outflow for the Company except in the period the notes were issued; therefore both are not indicative of our continuing operations.
|(2) Tax impact calculated using a 40% tax rate.|
The table above presents a reconciliation of GAAP to non-GAAP operating income, net income, and net income per share applicable to common stockholders for the three and twelve months ended December 31, 2016 and 2015. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, and stock-based compensation expense. Adjusted non-GAAP net income excludes the impact of tax affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, and non-cash interest expense on convertible senior notes.
|MEDIDATA SOLUTIONS, INC.|
|CONSOLIDATED BALANCE SHEETS|
|(Amounts in thousands, except per share data)|
|December 31, 2016||December 31, 2015|
|Cash and cash equivalents||$||93,519||$||49,562|
|Accounts receivable, net of allowance for doubtful accounts of $1,041 and $1,992, respectively||115,216||90,590|
|Prepaid commission expense||1,842||1,670|
|Prepaid expenses and other current assets||20,382||21,165|
|Deferred income taxes||6,536||88|
|Total current assets||518,780||383,201|
|Furniture, fixtures and equipment, net||58,461||51,043|
|Marketable securities, long-term||140,418||209,041|
|Intangible assets, net||5,090||1,172|
|Deferred income taxes, long-term||40,415||12,128|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accrued payroll and other compensation||29,260||23,744|
|Accrued expenses and other||20,958||15,469|
|Total current liabilities||132,331||121,078|
|1.00% convertible senior notes, net||263,401||249,487|
|Deferred revenue, less current portion||1,703||2,993|
|Deferred tax liabilities||322||414|
|Other long-term liabilities||18,138||26,052|
|Total noncurrent liabilities||283,564||278,946|
|Commitments and contingencies|
|Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding||—||—|
|Common stock, par value $0.01 per share; 200,000 shares authorized; 61,393 and 59,455 shares issued; 57,733 and 56,311 shares outstanding, respectively||614||594|
|Additional paid-in capital||418,497||364,973|
|Treasury stock, 3,660 and 3,144 shares, respectively||(114,204||)||(100,806||)|
|Accumulated other comprehensive loss||(5,276||)||(3,404||)|
|Total stockholders' equity||401,990||284,156|
|Total liabilities and stockholders' equity||$||817,885||$||684,180|
|MEDIDATA SOLUTIONS, INC.|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|(Amounts in thousands)|
|Twelve Months Ended December 31,|
|Cash flows from operating activities:||(unaudited)|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Depreciation and amortization||15,349||10,822|
|Amortization of discounts or premiums on marketable securities||2,757||4,754|
|Deferred income taxes||5,895||(3,209||)|
|Amortization of debt issuance costs||1,278||1,278|
|Amortization of debt discount||12,636||11,902|
|Provision for doubtful accounts||1,116||597|
|Loss on fixed asset disposal||3||—|
|Changes in operating assets and liabilities:|
|Prepaid commission expense||(2,108||)||439|
|Prepaid expenses and other current assets||185||(9,058||)|
|Accrued payroll and other compensation||7,343||6,014|
|Accrued expenses and other||14,220||712|
|Other long-term liabilities||(7,914||)||5,872|
|Net cash provided by operating activities||88,769||88,594||(1||)|
|Cash flows from investing activities:|
|Purchase of furniture, fixtures and equipment (2)||(25,656||)||(19,017||)|
|Purchase of available-for-sale marketable securities||(266,361||)||(264,113||)|
|Proceeds from sale of available-for-sale marketable securities||271,796||246,423|
|Purchase of cost method investment||(4,000||)||—|
|Acquisition of business, net of cash acquired||(17,186||)||—|
|Net decrease (increase) in restricted cash||149||(791||)|
|Net cash used in investing activities||(41,258||)||(37,498||)|
|Cash flows from financing activities:|
|Proceeds from exercise of stock options||5,495||6,686|
|Proceeds from employee stock purchase plan||6,864||6,009|
|Repayment of obligations under capital leases||—||(46||)|
|Acquisition of treasury stock||(15,570||)||(53,582||)|
|Repayment of notes payable||(100||)||(62||)|
|Net cash used in financing activities||(3,311||)||(40,995||)||(1||)|
|Effect of exchange rate changes on cash and cash equivalents||(243||)||(56||)|
|Net increase in cash and cash equivalents||43,957||10,045|
|Cash and cash equivalents - Beginning of period||49,562||39,517|
|Cash and cash equivalents - End of period||$||93,519||$||49,562|
(1) As a result of the Company's early adoption of Accounting Standards Update No. 2016-09, which requires excess tax benefit on equity awards to be presented as an operating activity, the consolidated statement of cash flows for the twelve months ended December 31, 2015 has been adjusted to reflect an offsetting increase of $1,622 thousand to net cash provided by operating activities and net cash used in financing activities.
(2) Purchases of furniture, fixtures and equipment include capitalized software development and implementation costs of $3,262 thousand and $954 thousand for the twelve months ended December 31, 2016 and 2015, respectively.